SCLX News & Events

Scilex files to sell 2.08M shares of common stock

Scilex files to sell 6.58M shares of common stock for holders

Scilex (SCLX) announced that its board of directors approved a dividend of Semnur Pharmaceuticals (SMNR) common stock held by the company to its stockholders and certain other eligible equityholders of Scilex. The record date for the dividend is June 1. "The Participating Holders as of the Record Date will be entitled to receive one (1) share of common stock of Semnur for each share of Scilex common stock held or for each share of common stock issuable or deemed issuable upon exercise or conversion of such other eligible securities. Scilex currently holds approximately 186 million shares of Semnur common stock and plans to distribute approximately 10.7 million of such shares to the Participating Holders based on the foregoing ratio. The Record Date for the dividend may be changed by the Board for any reason at any time prior to the actual payment date, and payment of the dividend is conditioned upon the Board having not revoked the dividend prior to the payment date, including for a material change to the solvency or surplus analysis presented to the Board," Scilex stated.

Datavault AI (DVLT) entered into a fully binding term sheet with Wellgistics Health (WGRX), integrating proprietary pharmacy dispensing optimization artificial intelligence platform EinsteinRx into its PharmacyChain, to build Wellgistics into DelivMeds AI following the completion of three concurrent transactions: 1) the expansion of Datavault AI's previously disclosed PharmacyChain license to include Healthcare-as-a-Service-related intellectual property; 2) the acquisition of the QOLPOM intellectual property from EOS Technology Holdings and Scilex Holding Company (SCLX) that enables wearables-driven biometric confirmation of pharmacodynamic drug effect and biometric confirmation named-patient to receive home drug delivery; and 3) the acquisition of a controlling stake in Tollo Health. Together, the three transactions forming DelivMeds carry an expected approximate combined asset value of $4 billion, subject to an independent fairness opinion.